Osimertinib: Difference between revisions
Jump to navigation
Jump to search
New page: <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> Osimertinib, sold under the brand name Tagrisso,[4] is a medication used to treat non-small... |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | ||
Osimertinib, sold under the brand name Tagrisso,[ | Osimertinib, sold under the brand name Tagrisso,<ref name="a4">[https://www.who.int/medicines/publications/druginformation/INN_List113.pdf "Proposed INN: List 113"] (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015</ref> is a medication used to treat non-small-cell lung carcinomas with specific mutations.[5][6] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 13:58, 9 October 2023
Osimertinib, sold under the brand name Tagrisso,[1] is a medication used to treat non-small-cell lung carcinomas with specific mutations.[5][6] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
|
| ||||||||||
ReferencesReferences
- ↑ "Proposed INN: List 113" (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015